Ipsen – September 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights
and shares composing the share capital
(in accordance with Article L.233-8 II of the French Commercial Code and
Article 223-16 of the General Regulation of the Autorité des Marchés Financiers)
Market: Euronext Paris
ISIN Code: FR 0010259150
LEI: 549300M6SGDPB4Z94P11
| Date | Total number of shares composing the share capital | Total number of voting rights (1) |
| 30 September 2024 | 83,814,526 | Gross total* of voting rights: 132,140,937 |
| Net total** of voting rights: 131,040,789 |
(1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10).
* Gross total = total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The « Gross total » is used as a basis for the calculation of threshold crossings.
** Net total = total number of voting rights attached to the total number of shares – shares without voting rights.
Attachment
Ipsen – October 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
Ipsen – August 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Testing video 1
Testing video 3
Testing video 2
IPSEN – Buy-back programme – Art 5 of MAR – Week 32 – 2024